A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Mandos LLC
- 入组人数
- 56
- 试验地点
- 58
- 主要终点
- Parts A/B: Change From Baseline to Week 52 in 4-Item Composite Score of Niemann Pick Type C Severity Scale (NPC-SS) Score
研究概览
简要总结
Due to different study designs, the sponsor separated Part C into a separate registration (NCT04958642), leaving Parts A/B here in NCT02534844.
This study is to find out how safe and effective VTS-270 is for patients with Niemann-Pick Type C1 (NPC1) disease who have neurologic symptoms (listed under Keywords).
In Parts A/B, two out of every three patients will receive the study drug. The third patient will receive 1 to 2 small needle pricks at the location where the LP and IT injection is normally made (sham control).
In Part C, all participants will receive study drug, as described in the Part C registration record.
Start date for this record is the first day a participant was enrolled in Parts A/B. The trial is actually continuing until the last primary outcome measure of safety data are collected from Part C participants. The last primary outcome measure of safety, along with final adverse events results will be posted in the separate Part C registration record.
详细描述
Non-clinical studies and a Phase 1 clinical trial suggest that intrathecal administration of VTS-270 in patients with neurologic manifestations of Niemann-Pick Type C1 (NPC1) disease has the potential to slow the rate of progression of their neurologic disease.
Niemann-Pick Type C1 (NPC1) disease is a rare, neurodegenerative, inherited, autosomal recessive lysosomal lipid storage disorder primarily in children and teenagers. The disease is characterized by the inability to properly metabolize cholesterol and other lipids within the cell due to mutations in the NPC1 gene, causing unesterified cholesterol to accumulate in the brain, liver and spleen.
This study plans to enroll about 51 participants with NPC1 disease. It will be conducted in three parts: Parts A, B, and C.
- Part A will evaluate 3 different dose levels of VTS-270 in 12 participants to determine the dose level for Parts B and C.
- In Part B, 39 more participants will join the original 12 to evaluate the safety and effectiveness of the dose selected from Part A compared to sham control.
- Part C will be an open-label extension phase of the study for Part B participants who either complete Part B or have met rescue therapy criteria, as well as participants entering Part C from other trials.
Participants in Part C will receive treatment with VTS-270 until the product is licensed or the program is terminated (anticipated within 5 years).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Care Provider, Investigator)
盲法说明
While it is a double-blind trial, the participant and outcomes assessor will be blinded, as well as the Care Provider and Investigator.
入排标准
- 年龄范围
- 4 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Had onset of neurological symptoms prior to 15 years of age
- •Has confirmed diagnosis of NPC1 determined by either:
- •two NPC1 mutations
- •positive filipin staining and at least one NPC1 mutation
- •vertical supranuclear gaze palsy (VSNGP) in combination with either: one NPC1 mutation, OR positive filipin staining or oxysterol levels consistent with NPC disease and no Niemann-Pick Type C2 (NPC2) Disease mutations
- •Adult participant or parent/guardian has provided written informed consent, with assent collected from minors of appropriate age
- •Is able to undergo a lumbar puncture (LP) and IT drug administration under conscious sedation or general anesthesia
- •Has an NPC Clinical Severity Scale Score of 1 through 4, inclusive, in two or more of the following components: ambulation, fine motor skills, or swallowing; and has a score of 0 through 4 on the cognition component
- •Has a total NPC Clinical Severity Scale Score of 10 or greater
- •If taking miglustat, must have been on a stable dose for past 6-8 weeks and be willing to remain on a stable dose
- •If participant has seizures, they have been adequately controlled for 3 months without changing dose or regimen
- •Has agreed to discontinue all non-prescription supplements at least 1 month prior to first dose (Study Day 0)
- •Has agreed to discontinue any other investigational treatments for NPC including vorinostat or arimoclomol at least 3 months prior to first dose (Study Day 0)
- •If of child-bearing potential (not surgically sterile), agrees to use a medically acceptable method continuously, until at least 30 days after participation in the study
排除标准
- •Has exclusion criteria as assessed by NPC Clinical Severity Scale:
- •Unable to walk, wheelchair dependent (ambulation NPC score=5)
- •Has need for a nasogastric tube to overcome swallowing difficulties (swallowing NPC score=5) unless used for supplemental feeding or administering medication
- •severe dysmetria (fine motor score =5) or
- •minimal cognitive function (cognition NPC score=5)
- •Weighs less than 15 kg
- •Has had prior treatment with intravenous 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for NPC1 disease, unless the subject has undergone a minimum 3-month washout period prior to Study Day 0, or has had any prior intrathecal (IT) administration of HP-β-CD
- •Is taking antipsychotics for treatment of psychosis; use of antipsychotic medication for treatment of other disorders (e.g., Attention Deficit Hyperactivity Disorder) will not exclude participation in this trial
- •Has a history of hypersensitivity reactions to any product containing HP-β-CD
- •Has a spinal deformity that could impact the ability to perform a lumbar puncture
- •Has had a skin infection in the lumbar region within 2 months of study entry
- •Has neutropenia, defined as an absolute neutrophil count (ANC) of less than 1.5 X 10^9/L
- •Has thrombocytopenia (platelet count of less than 75 X 10^9/L)
- •Has activated partial thromboplastin time (aPTT) or prothrombin time (PT) prolonged by > 1.5 times the upper limit of normal (ULN) or known history of a bleeding disorder
- •Has had status epilepticus occurring within 3 months of screening and/or seizure frequency that cannot be quantified
- •Has evidence of either obstructive hydrocephalus or normal pressure hydrocephalus
- •Has recently used anticoagulants [in past 2 weeks prior to first dose (Study Day 0); re: lumbar puncture safety].
- •Is unable to comply with the study procedures or has a clinical disease or laboratory abnormality that in the opinion of the investigator would potentially increase the risk of participation
结局指标
主要结局
Parts A/B: Change From Baseline to Week 52 in 4-Item Composite Score of Niemann Pick Type C Severity Scale (NPC-SS) Score
时间窗: Baseline, Week 52
The NPC-SS composite score is the sum of the ambulation, cognition, fine motor, and swallowing domains of the NPC-SS. Each of the four NPC-SS components (ambulation, cognition, fine motor, and swallowing) are rated on a scale from 0 (better) to 5 (worse). The total score was the sum of individual components scores which ranges from 0 (best) to 20 (worst), with higher scores indicating more severe clinical impairment.
Parts A/B: Number of Participants Classified With Each Score on the Clinician Global Impression of Change (CGIC) at Week 52
时间窗: Week 52
The Clinician CGIC is a 7-point Likert scale. The scale requires assessment of change from a baseline level of disease activity, with anchors ranging from markedly improved, moderately improved, and minimally improved to no change and corresponding worsening (minimally, moderately, markedly). The Investigator rates his/her impression of the change in each participant's condition at week 52 on a scale from marked improvement (1) to marked worsening (7).
次要结局
- Parts A/B: Change From Baseline to Week 52 in NPC-SS Total Score (Excluding Hearing and Auditory Brainstem Response [ABR])(Baseline, Week 52)
- Parts A/B: Number of Participants With Treatment Emergent Adverse Events (TEAEs)(Baseline up to Week 52)
- Parts A/B: Change From Baseline to Week 52 in Each of the 9 Clinical Domains of the NPC-SS(Baseline, Week 52)
- Parts A/B: Time to One Point Increase (Worsening) in NPC-SS Composite Score(Baseline up to Week 52)
- Parts A/ B: Number of Participants Classified as CGIC Responders at Week 52(Week 52)
- Parts A/B: Change From Baseline to Week 52 in Mean Annualized Rate of Change (Slope) of NPC-SS Composite Score(Baseline, Week 52)
- Parts A/B: EQ-5D-3L Questionnaire Visual Analog Scale (VAS) Score (for Health Status) at Baseline and at Week 52(Baseline, Week 52)
- Parts A/B: Number of Participants Treated for at Least 6 Months Who Qualified for the Rescue Option(Baseline up to Week 26)
- Parts A/B: Change From Baseline to Week 52 in the Total NPC-SS (With Hearing Domain and ABR Modifier Included)(Baseline, Week 52)
- Parts A/B: Number of Participants Classified as Responders on NPC-SS Total Score (Excluding Hearing and ABR) at Week 52(Week 52)
- Parts A/B: Change From Baseline in the Timed Up and Go (TUG) Test at Week 52(Baseline, Week 52)
- Parts A/B: Change From Baseline in the 9-Hole Peg Test at Week 52(Baseline, Week 52)